Advancing Integrated Therapies for Gaucher Disease
NCT07758816 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2026-08-11
Summary
The purpose of this study is to better understand the natural history, clinical outcomes, and biological features of Gaucher disease in patients receiving standard medical care
Conditions
Sponsors & Collaborators
-
Sanofi-Yale External Research Collaboration
collaborator UNKNOWN -
Yale University
lead OTHER
Principal Investigators
-
Pramod K Mistry, MD, PhD · Yale University
Eligibility
- Min Age
- 3 Months
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-05-06
- Primary Completion
- 2030-09-30
- Completion
- 2030-09-30
Countries
- United States
Study Locations
More Related Trials
-
Retrospective and Prospective Observational Study of MRI Changes in Bone and Visceral Lesions of Patients With Type 1 Gaucher Disease Treated With VPRIV® (Velaglucerase Alfa)
NCT03333447 ·Status: COMPLETED
-
A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease
NCT04721366 ·Status: COMPLETED
-
Study to Evaluate Blood Cell Lines From Patients With Gaucher Disease
NCT00351156 ·Status: COMPLETED
-
The Natural History of Infantile Globoid Cell Leukodystrophy
NCT00983879 ·Status: COMPLETED
-
A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease
NCT01411228 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease
NCT00635427 ·Status: COMPLETED ·Phase: PHASE3
-
Bone Response to Enzyme Replacement in Gaucher's Disease
NCT00001416 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Enzyme Replacement in Gaucher's Disease
NCT00001289 ·Status: COMPLETED
-
Krabbe Disease Global Patient Registry
NCT02993796 ·Status: RECRUITING
-
Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease
NCT01842841 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease
NCT00954460 ·Status: APPROVED_FOR_MARKETING
-
Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease
NCT00004293 ·Status: UNKNOWN ·Phase: PHASE2
-
Genetic Studies of Lysosomal Storage Disorders
NCT00001215 ·Status: ENROLLING_BY_INVITATION
-
Translational Potential of ex Vivo Gene Therapy in GM2 Gangliosidosis
NCT07445490 ·Status: NOT_YET_RECRUITING
-
Clinical Study of AAV1-gamma-sarcoglycan Gene Therapy for Limb Girdle Muscular Dystrophy Type 2C
NCT01344798 ·Status: COMPLETED ·Phase: PHASE1
-
A Natural History Study of the Gangliosidoses
NCT00668187 ·Status: RECRUITING
-
Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)
NCT01136304 ·Status: COMPLETED
-
Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2
NCT04470713 ·Status: COMPLETED
-
Digital Health Platform Customized for Patients With Gaucher Disease
NCT04997772 ·Status: COMPLETED
-
PEG-Glucocerebrosidase for the Treatment of Gaucher Disease
NCT00001410 ·Status: COMPLETED ·Phase: PHASE1
-
Immune Biomarkers Related to Bone Pathology in Patients With Type 1 Gaucher Disease
NCT04055831 ·Status: UNKNOWN
-
Implementation and Evaluation of a Rare Disease Algorithm to Identify Persons at Risk of Gaucher Disease Using Data From Electronic Health Records (EHRs) in the United States (Project Searchlight)
NCT05908656 ·Status: COMPLETED ·Phase: NA
-
A Non-Interventional National Study in Pediatric Patients With Unexplained Enlarged Spleen
NCT04845958 ·Status: COMPLETED
-
Liver and the Spleen Stifness in Adult Patients With Gaucher's Disease Using Ultrasound Shear Wave Elastography
NCT03896607 ·Status: TERMINATED
-
Sun May Arise on SMA : Newborn Screening of Spinal Muscular Atrophy in Belgium
NCT03554343 ·Status: COMPLETED